Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4819-4828

  Imai, Hisao ^a   Kaira, Kyoichi ^a   Oriuchi, Noboru ^a   Shimizu, Kimihiro ^a   Tominaga, Hideyuki ^a   Yanagitani, Noriko ^a   Sunaga, Noriaki ^a   Ishizuka, Tamotsu ^a   Nagamori, Shushi ^b   Promchan, Kanyarat ^b   Nakajima, Takashi ^a,c   Yamamoto, Nobuyuki ^c   Mori, Masatomo ^a   Kanai, Yoshikatsu ^b  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

Author keywords

EGFR mutation; LAT1; MTOR; Non small cell lung cancer; NSCLC

Indexed keywords

2 AMINOBICYLCO (2,2,1) HEPTANE 2 CARBOXYLIC ACID; AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; CD98 ANTIGEN; GEFITINIB; K RAS PROTEIN; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADULT; AGED; AMINO ACID TRANSPORT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL FEATURE; CONCENTRATION RESPONSE; CYTOTOXICITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS, CYCLIC; ANTIGENS, CD98; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LEUCINE; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TOR SERINE-THREONINE KINASES;

EID: 78751476207     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Novell S and Le Chevalier T: Chemotherapy for non-small cell lung cancer: Part 1. Early-stage disease. Oncology (Williston Park) 17: 357-364, 2003.
2. NSCLC Meta-Analysis Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced nonsmall cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-4625, 2008.
3. Socinski MA, Morris DE, Masters GA and Lilenbaum R: American College of Chest Physicians: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123: 226S-43S, 2003.
4. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sei 95: 1817-1824, 2007.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
6. Christensen HN: Role of amino acid transport and counter transport in nutrition and metabolism. Physiol Rev 70: 43-77, 1990.
7. McGivan JD and Pastor-Anglada M: Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 299: 321-334, 1994.
8. Oxender DL and Christensen HN: Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 197: 765-767, 1963.
9. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273: 23629-23632, 1998.
10. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K,Takeda E, Goya T and Endou H: Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514: 291-302, 2001.
11. Ohkame H, Masuda H, Ishii Y and Kanai Y: Expression of Ltype amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol 78: 265-71;
12. discussion 271-272, 2001.
13. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T,Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M: Prognostic significance of L-type amino acid transporter 1 expression in resectable stage 1-III nonsmall cell lung cancer. Br J Cancer 95: 742-748, 2008.
14. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Iijima H, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M: Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 204: 553-561, 2008.
15. Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Aida S, Kasamatsu H and Kawai T: Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 451: 681-690, 2007.
16. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y and Endou H: L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119: 484-492, 2006.
17. Fuchs BC and Bode BP: Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Seminars in Cancer Biology 15: 254-266, 2006.
18. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D and Sonenberg N: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94: 195-9, 2006.
19. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signaling contro;s tumour cell growth. Nature 441: 424-430, 2006.
20. Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y and Kohno N: System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Letters 276: 95-101, 2009.
21. La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D and Petronini PG: Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochemical Pharm 75: 460-468, 2009.
22. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F and Tortora G: Inhibition of mTOR pathway by everplimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR. Br J Cancer 95: 923-930, 2008.
23. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF and Minna JD: RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 64: 3137-43, 2004.
24. Kim DK, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua A, Babu E, Tachampa K, Anzai N, Iribe Y and Endou H: Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim. Biophys. Acta 1565: 112-121, 2002.
25. Mountain CF: Revision in the international System for staging lung cancer. Chest //:1710-1717, 1997.
26. Yokota J, Wada M, Shimosato Y, Terada M and Sugimura T: Loss of heterozygosity on chromosomes 3, 13, and 17 in smallcell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 84: 9252-9256, 1987.
27. Chairoungdua A, Segawa H, Kim JY, Miyamoto K, Haga H, Fukui Y, Mizoguchi K, Ito H, Takeda E, Endou H and Kanai Y: Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem274: 28845-28848, 1999.
28. Kaira k, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Dobashi K, Kanai Y, Endou H, Nakajima T, Endo K and Mori M: Fluorine18-ct-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A clinicopathological study. Clin Cancer Res 13: 6369-6378, 2007.
29. 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 124: 1152-1160, 2008.
30. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M: L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 99: 2380-2386, 2008.
31. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. Engl N Med J 324: 1-8, 1991.
32. Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y and Tsuneyoshi M: CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Modern Pathol 19: 738-745, 2006.
33. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R and Buttitta F: EGFR mutations in nonsmall-cell lung cancer: Analysis of a large series of cases and development of rapid and sensitive method for diagnostic screening with potential implication on pharmacological treatment. J Clin Oncol 23: 857-865, 2005.
34. Mitani Y, Lezhava A, Kawai Y, Kikuchi T, Oguchi-Katayama A, Kogo Y, Itoh M, Miyagi T, Takakura H, Hoshi K, Kato C, Arakawa T, Shibata K, Fukui K, Masui R, Kuramitsu S, Kiyotani K, Chalk A, Tsunekawa K, Murakami M, Kamataki T, Oka T, Shimada H, Cizdziel PE and Hayashizaki Y: Rapid diagnostics using asymmetric isothermal amplification and a new mismatch suppression technology. Nat Methods 4: 257-262, 2007.
35. Hoshi K, Takakura H, Mitani Y, Tatsumi K, Momiyama N, Ichikawa Y, Togo S, Miyagi T, Kawai Y, Kogo Y, Kikuchi T, Kato C, Arakawa T, Uno S, Cizdziel PE, Lezhava A, Ogawa N, Hayashizaki Y and Shimada H: Rapid detection of epidermal growth factor receptor mutations in lung cancer by the smartamplification process. Clin Cancer Res 13: 4974-4983, 2007.
36. Tatsumi K, Mitani Y, Watanabe J, Takakura H, Hoshi K, Kawai Y, Kikuchi T, Kogo Y, Oguchi-Katayama A, Tomaru Y, Kanamori H, Baba M, Ishidao T, Usui K, Itoh M, Cizdziel PE, Lezhava A, Ueda M, Ichikawa Y, Endo I, Togo S, Shimada H and Hayashizaki Y: Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol. Diag 10: 520-526, 2008.
37. Kanai Y and Endou H: Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance, Curr. Drug Metab 2: 339-354, 2001.
38. Peyrollier K, Hajduch E, Blair AS, Hyde R and Hundal HS: LLeucine availability regulates phosphatidylinositol 3-kinase, p70S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport. Biochem J 350: 361-368,2000.
39. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA and Sellers WR: mTOR inhibition reverses AKt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-I-dependent pathways. Nat Med 10: 594-601, 2004.
40. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW and Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther 5: 2676-2684, 2006.
41. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Nakajima T and Mori M: Prognostic significance of L-type amino acid transporter I (LATl) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 66: 120-126, 2009.
42. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T and Mori M: Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 100: 249-254, 2009.
43. Kosaka T, Yatabe Y, Onozato R, Kuwano H and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4: 22-429, 2009.
44. Takeuchi K, Ogata S, Nakanishi K, Ozeki Y, Hiroi S, Tominaga S, Aida S, Matsuo H, Sakata T and Kawai T: LAT1 expression in non-small-cell lung carcinomas: analysis by semiquantitative reverse transcription-PCR (237cases) and immunohistochemistry (295cases). Lung Cancer 65: 58-65, 2010.